抄録
Azithromycin hydrate (AZM) is a new macrolide antimicrobial. In this study, we evaluated the clinical efficacy of AZM for acute sinusitis. The patients were randomly divided into two groups. Twenty-five patients (Group A) were given a daily 500-mg oral dose of AZM for 3 days, and 26 patients (Group B) were given the same dose of AZM two times with a 1-week interval. The clinical efficacy rate was 85.2% in Group A and 88% in Group B, and there was no significant difference in the efficacy rates between these groups. These findings suggested that AZM was useful for the treatment of acute sinusitis and that a 500-mg oral dose of AZM for 3 days should be sufficient.
